FGFR1 and breast carcinoma: For example, FGFR1 amplification has been found in up to 20% of squamous non-small cell lung carcinomas (NSCLC), 18% of osteosarcomas, 10% of breast carcinomas, and 6% of small cell lung carcinomas [7,8,9], and was associated with sensitivity to FGFR inhibitors in preclinical in vivo models.